Non-contrast transcatheter aortic valve implantation for patients with aortic stenosis and chronic kidney disease: a pilot study

被引:4
|
作者
Freire, Antonio Fernando Diniz [1 ]
Nicz, Pedro Felipe Gomes [1 ]
Ribeiro, Henrique Barbosa [1 ]
Filippini, Filippe Barcellos [1 ]
Accorsi, Tarso Duenas [1 ]
Liberato, Gabriela [1 ]
Nomura, Cesar Higa [1 ]
Cassar, Renata de Sa [1 ]
Vieira, Marcelo Luiz Campos [1 ]
Mathias Jr, Wilson [1 ]
Pomerantzeff, Pablo Maria Alberto [1 ]
Tarasoutchi, Flavio [1 ]
Abizaid, Alexandre [1 ]
Kalil Filho, Roberto [1 ]
de Brito Jr, Fabio Sandoli [1 ]
机构
[1] Univ Sao Paulo InCor, Dept Intervent Cardiol, Heart Inst, Sao Paulo, Brazil
来源
关键词
transcatheter aortic valve replacement; aortic stenosis; renal failure; zero contrast; renal insufficiency; OUTCOMES; INJURY; REPLACEMENT; PREDICTORS; IMPACT;
D O I
10.3389/fcvm.2023.1175600
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAcute kidney injury (AKI) is frequently observed after transcatheter aortic valve implantation (TAVI). Of note, it is associated with a threefold increase in all-cause and cardiac death. We propose a new non-contrast strategy for evaluating and performing the TAVI procedure that can be especially valuable for patients with aortic stenosis (AS) and chronic kidney disease (CKD) to prevent AKI. MethodsPatients with severe symptomatic AS and CKD stage & GE;3a were evaluated for TAVI using four non-contrast imaging modalities for procedural planning: transesophageal echocardiogram (TEE), cardiac magnetic resonance, multidetector computed tomography (MDCT), and aortoiliac CO2 angiography. Patients underwent transfemoral (TF) TAVI using the self-expandable Evolut R/Pro, and the procedures were guided by fluoroscopy and TEE. Contrast MDCT and contrast injection at certain checkpoints during the procedure were used in a blinded fashion to guarantee patient safety. ResultsA total of 25 patients underwent TF-TAVI with the zero-contrast technique. The mean age was 79.9 & PLUSMN; 6.1 years, 72% in NYHA class III/IV, with a mean STS-PROM of 3.0% & PLUSMN; 1.5%, and creatinine clearance of 49 & PLUSMN; 7 ml/min. The self-expandable Evolut R and Pro were implanted in 80% and 20% of patients, respectively. In 36% of the cases, the transcatheter heart valve (THV) chosen was one size larger than the one by contrast MDCT, but none of these cases presented adverse events. Device success and the combined safety endpoint (at 30 days) both achieved 92%. Pacemaker implantation was needed in 17%. ConclusionThis pilot study demonstrated that the zero-contrast technique for procedural planning and THV implantation was feasible and safe and might become the preferable strategy for a significant population of CKD patients undergoing TAVR. Future studies with a larger number of patients are still needed to confirm such interesting findings.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] CHRONIC KIDNEY DISEASE IMPACTS OUTCOMES IN TRANSCATHETER AORTIC VALVE IMPLANTATION
    Kiat, Julian Tay Cheong
    Yap, Jonathan
    Ewe, See Hooi
    Thiagarajan, Nishanth
    Chia, Shaw Yang
    Rizwan, Mohammed
    Lim, Soo Teik
    Chao, Victor
    Ho, Kay Woon
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1249 - 1249
  • [22] Impact of Chronic Kidney Disease on Outcomes in Transcatheter Aortic Valve Implantation
    Yap, Jonathan J. L.
    Tay, Julian C. K.
    Ewe, See Hooi
    Thiagarnjan, Nishanth
    Chia, Shaw Yang
    Amanullah, Mohammed Rizwan
    Lim, Soo Teik
    Chao, Victor T. T.
    Ho, Kay Woon
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2020, 49 (05) : 273 - 284
  • [23] Evolution of chronic kidney disease after surgical aortic valve replacement or transcatheter aortic valve implantation
    Reuillard, Adrien
    Garrouste, Cyril
    Pereira, Bruno
    Azarnoush, Kasra
    Souteyrand, Geraud
    Aniort, Julien
    Innorta, Andrea
    Clerfond, Guillaume
    Heng, Anne Elisabeth
    Eschalier, Romain
    Motreff, Pascal
    Combaret, Nicolas
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2019, 112 (03) : 162 - 170
  • [24] Transcatheter aortic valve implantation in patients with advanced chronic kidney disease: futility or reliability?
    Conrotto, F.
    Andreis, A.
    Salizzoni, S.
    D'Onofrio, A.
    Agrifoglio, M.
    Chieffo, A.
    Regesta, T.
    Gabbieri, D.
    Saia, F.
    D'Ascenzo, F.
    D'Amico, M.
    Moretti, C.
    Rinaldi, M.
    Gaita, F.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1398 - 1399
  • [25] Treatment of Aortic Stenosis With Transcatheter Aortic Valve Implantation
    Otto, Catherine M.
    Song, Jae-Kwan
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (19): : 1870 - 1871
  • [26] Transcatheter aortic valve implantation versus conservative treatment in chronic kidney disease patients
    Steinmetz, Tali
    Witberg, Guy
    Chagnac, Avry
    Green, Hefziba
    Sagie, Alexander
    Rozen-Zvi, Benaya
    Kornowski, Ran
    EUROINTERVENTION, 2018, 14 (05) : 503 - 510
  • [27] TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH PRE-EXISTING CHRONIC KIDNEY DISEASE
    Rahman, Mohammed Shamim
    Sharma, Rajan
    Brecker, Stephen J. D.
    HEART, 2015, 101 : A52 - A52
  • [28] Transcatheter Aortic-Valve Implantation for Aortic Stenosis
    Newman, Jonathan
    Shimbo, Daichi
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (02): : 180 - 180
  • [29] Transcatheter Aortic Valve Implantation is effective for Aortic Stenosis
    Di Lellis, Maddalena Angela
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (17) : 992 - 993
  • [30] Effect of Transcatheter Aortic Valve Implantation on Renal Function in Patients With Chronic Kidney Disease
    Takada, Takuma
    Jujo, Kentaro
    Konami, Yutaka
    Otsuki, Hisao
    Tanaka, Kazuki
    Saito, Chihiro
    Isomura, Shogo
    Domoto, Satoru
    Yamaguchi, Junichi
    Niinami, Hiroshi
    Hagiwara, Nobuhisa
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 126 : 82 - 88